Anselamimab

DB17492InvestigationalProtein Based Therapies

Anselamimab: Overview.

Mechanism
Curator reviewed
Also known as
Chimeric fibril reactive monoclonal antibody 11-1F4 · IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS IMMUNOGLOBULIN LIGHT CHAIN AMYLOID (AL) FIBRILS), CHIMERIC MONOCLONAL ANTIBODY (GAMMA1 HEAVY CHAIN CHIMERIC (1-441) (MUS MUSCULUS VH (IGHV2-3*01 (92.6%)-(IGHD)-IGHJ4*01 (92.9%), CDR-IMGT (8.7.5) (26-33.51-57.96
Code names
11-1F4 · CAEL-101

Resolves to

Compound
UNIITL94QQ5RTWCAS2414866-63-8
Targets
P0DOX7Immunoglobulin kappa light chainP0DOX8Immunoglobulin lambda-1 light chain

What you can answer from here — as of July 13, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Anselamimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In